MPC 75

The consumption impulse from pandemic savings ‒ does the composition matter?

Retrieved on: 
Friday, June 30, 2023
Autumn, U.S. Department of the Treasury, Office of Inspector General, Housing, Journal of Economic Dynamics and Control, MPC, Office of Inspector General, U.S. Department of Health and Human Services, Excess, Economics Bulletin, Speech, Survey of Consumer Finances, Economy, COVID-19, Coronavirus, Control, DFA, Consumption, MPC 75, USD, Government, Household Finance and Consumption Survey (Ireland), Economics, HSBC Finance, Treasury, Education for Economic Security Act, NBER, Journal, ECB, Income, 2018 Arkansas Issue 5, United, Volition, HFCS, SCF, Calibration, Tourism, Real estate, Bank, Bookkeeping, Security (finance), Atlantic Ocean
Key Points: 

Appendix 4C Quarterly Activity Report

Retrieved on: 
Friday, April 28, 2023
DREAM, MESO, Executive, Neural correlates of consciousness, Myocardial infarction, MI, Symantec Endpoint Protection, LVEF, Stroke, Heart, Hyaluronic acid, Mesoblast, MPC 75, Pain, Journal, Prescription Drug User Fee Act, Patient, Survival, PDUFA, CRL, MSB, American College, FDA, CHF, Appendix, Complete Response Letter, BLA, JACC, PLI, Inflammation, Video game, Pharmaceutical industry

NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2023.

Key Points: 
  • NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2023.
  • Successful completion of a global private placement primarily to Mesoblast’s existing major US, UK, and Australian shareholders raising approximately US$40 million, net of transaction costs.
  • Revenue from royalties on sales of TEMCELL® HS Inj.1 sold in Japan by our licensee for the quarter were US$1.8 million.
  • The data from both studies formed key components of Mesoblast’s recent resubmission of its remestemcel-L BLA to FDA for children with SR-aGVHD.

DREAM-HF Phase 3 Trial Results for Mesoblast Cell Therapy in Heart Failure Published in Journal of the American College of Cardiology (JACC)

Retrieved on: 
Monday, February 27, 2023
DREAM, Marketing, CHF, The Texas Heart Institute, LVEF, FACC, Knowledge, American College, MPC 75, Doctor of Philosophy, Heart failure with preserved ejection fraction, MD, Survival, Stroke, HF, MPC, MSB, Heart, MACE, Inflammation, JACC, Research, MESO, Risk, American Heart Journal, Cell, Plaque, Journal, FDA, NYHA, Myocardial infarction, Patient, LVAD, Heart failure, Regenerative medicine, Blood, Mesoblast, Cardiomyopathy, Splenic infarction, US Foods, GI, Nosebleed, Hospital, Membrane protein, Incidence, MI, Pharmaceutical industry, Medical imaging, Cardiology

NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced publication of the DREAM-HF Phase 3 trial results in the premier peer-reviewed journal for cardiovascular medicine, the Journal of the American College of Cardiology (JACC).

Key Points: 
  • NEW YORK, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced publication of the DREAM-HF Phase 3 trial results in the premier peer-reviewed journal for cardiovascular medicine, the Journal of the American College of Cardiology (JACC).
  • Locally, in the heart, the MPCs can protect cardiac muscle cells from dying and can improve blood flow and energetics.
  • In large blood vessels throughout the body, the reduced inflammation resulting from the activation of MPCs may decrease plaque instability, which is what leads to heart attacks and strokes.
  • “The results of DREAM-HF suggest those patients with heart failure with preserved ejection fraction (HFpEF) and other cardiomyopathies could potentially benefit from MPC therapy as well.